Treatment of Spontaneous Bacterial Peritonitis
For community-acquired SBP, initiate empirical treatment immediately with intravenous cefotaxime 2g every 6-8 hours or ceftriaxone 1-2g every 12-24 hours for 5-7 days, plus IV albumin (1.5 g/kg at diagnosis and 1 g/kg on day 3) to reduce mortality from 29% to 10%. 1, 2, 3
Empirical Antibiotic Selection
Community-Acquired SBP
The most recent guidelines consistently recommend third-generation cephalosporins as first-line therapy because they cover the most common causative organisms (E. coli, Klebsiella pneumoniae, and Streptococcus species) 1, 2:
- Cefotaxime 2g IV every 6-8 hours (most extensively studied, 77-98% resolution rate)
- Ceftriaxone 1-2g IV every 12-24 hours (73-100% resolution rate, equivalent efficacy)
Treatment duration: 5-7 days is as effective as 10 days 1, 3
Alternative Options for Community-Acquired SBP
- Amoxicillin-clavulanic acid (1g/0.2g IV every 8 hours, then 500mg/125mg PO every 8 hours): Similar efficacy to cefotaxime with lower cost 2
- Oral ofloxacin (400mg every 12 hours): Only for uncomplicated SBP without renal failure, hepatic encephalopathy, GI bleeding, ileus, or shock 2, 1
Critical caveat: Avoid quinolones if the patient is already on quinolone prophylaxis, in areas with high quinolone resistance (>30%), or for nosocomial SBP 2, 1, 2. Korean data shows E. coli quinolone resistance as high as 31.7% 1.
Nosocomial/Healthcare-Associated SBP
For hospital-acquired SBP or patients with sepsis/septic shock, use broad-spectrum antibiotics as first-line therapy 3:
- Meropenem plus daptomycin is significantly more effective than ceftazidime (86.7% vs 25% resolution) for nosocomial SBP 4
- Consider piperacillin-tazobactam or carbapenems based on local susceptibility patterns 3, 5
Albumin Administration: The Mortality Game-Changer
Albumin is not optional—it reduces mortality by two-thirds (from 29% to 10%, p=0.01) 2:
Dosing regimen:
- 1.5 g/kg IV at diagnosis (day 1)
- 1.0 g/kg IV on day 3
Who benefits most: Patients with baseline serum bilirubin ≥4 mg/dL OR creatinine ≥1 mg/dL have the greatest mortality reduction 2, 3. However, all patients with SBP should receive albumin unless contraindicated 3.
The mechanism extends beyond volume expansion—albumin prevents hepatorenal syndrome (reduces incidence from 30% to 10%) and improves circulatory function 2.
Monitoring Treatment Response
Perform repeat paracentesis at 48 hours to assess treatment efficacy 3:
- Treatment failure: PMN count fails to decrease to <25% of baseline value 2
- Treatment success: PMN count <250/mm³ and clinical improvement 2
If treatment fails, suspect:
- Antibiotic-resistant organisms → Broaden coverage based on culture sensitivities
- Secondary bacterial peritonitis → Obtain abdominal CT imaging 1, 2
Critical Diagnostic Criteria
Start empirical antibiotics immediately when:
- Ascitic fluid PMN >250/mm³ (regardless of culture results) 1
- **PMN <250/mm³ BUT clinical signs of infection** (fever >37.8°C, abdominal pain/tenderness) → Treat until cultures available 1
Common Pitfalls to Avoid
- Don't delay antibiotics waiting for culture results—empirical therapy must start immediately 2
- Avoid aminoglycosides (e.g., tobramycin)—they are nephrotoxic and less effective (56% vs 77-98% resolution with cephalosporins) 2
- Don't use quinolones blindly—resistance is increasing, particularly in patients previously exposed to quinolones 1
- Don't forget albumin—it's as important as antibiotics for reducing mortality 2, 3
- Temporarily hold non-selective beta-blockers if patient develops hypotension (MAP <65 mmHg) or acute kidney injury 3
When to Suspect Secondary Peritonitis
Obtain abdominal CT if 1:
- PMN count >1,000/mm³
- Multiple organisms on Gram stain or culture
- Ascitic total protein ≥1 g/dL
- Ascitic LDH above normal serum upper limit
- Ascitic glucose ≤50 mg/dL
- PMN count doesn't decrease after 48 hours of antibiotics
- Ascitic CEA >5 ng/mL or alkaline phosphatase >240 U/L
Adjusting Antibiotics Based on Culture
Once culture and sensitivity results return, tailor antibiotics to the specific organism 1. The increasing prevalence of multidrug-resistant organisms (MDRO) is associated with doubled in-hospital mortality (OR=2.24) 6, making culture-directed therapy increasingly important.